Put companies on watchlist
Eckert & Ziegler SE
ISIN: DE0005659700
WKN: 565970
Curious about what AI knows about Eckert & Ziegler? Just one click more
More AI Integrations
About
Company Snapshot
New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

Eckert & Ziegler SE · ISIN: DE0005659700 · EQS - Company News (157 News)
Country: Germany · Primary market: Germany · EQS NID: 2115452
10 April 2025 03:00PM

US Consul Visits Radiopharmaceutical Production in Braunschweig


EQS-News: Eckert & Ziegler SE / Key word(s): Miscellaneous
Eckert & Ziegler: US Consul Visits Radiopharmaceutical Production in Braunschweig

10.04.2025 / 15:00 CET/CEST
The issuer is solely responsible for the content of this announcement.


Berlin, 10 April 2025. US Consul General Jason Chue today visited the Eckert & Ziegler production site in Braunschweig and gained an impression of the production of radiopharmaceuticals for cancer diagnostics and therapy. Eckert & Ziegler maintains a long-standing relationship with the USA. The isotope specialist generates almost 40% of its sales in the USA and has four production sites in three states. Today, the company counts over 170 employees in the United States.

For the treatment of cancer using radioligand therapy, Eckert & Ziegler produces the radiopharmaceutical Theralugand® (non-carrier added lutetium-177 chloride) in Braunschweig. Lu-177 based radiopharmaceuticals are currently used to treat neuroendocrine tumors and metastatic prostate cancer.

In order to meet the growing global demand for lutetium-177 and ensure a stable supply of this important therapeutic radioisotope, Eckert & Ziegler is currently expanding its production capacities and investing around EUR 10 million in the construction of a lutetium production facility at its US production site in Wilmington (Boston) which is expected to go into operation in 2027.

“Eckert & Ziegler is a great example of balanced transatlantic cooperation,” summarized Jason Chue at the end of the visit. The company is not only a market leader with radioactive components for medicine and measurement technology “Made in the USA” and “Made in Germany”, but also contributes to helping cancer patients worldwide with its products.

“Our mission is to improve diagnosis and therapy. By providing our high-quality radionuclides, we make a decisive contribution to the further development of nuclear medicine therapy approaches,” added Dr. Harald Hasselmann, Chairman of the Executive Board of Eckert & Ziegler SE.

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1.000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact:
Eckert & Ziegler SE
Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138
karolin.riehle@ezag.de
www.ezag.com 



10.04.2025 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com


Language: English
Company: Eckert & Ziegler SE
Robert-Rössle-Str.10
13125 Berlin
Germany
Phone: +49 30 941084-138
Fax: +49 30 941084-0
Internet: www.ezag.de
ISIN: DE0005659700
WKN: 565970
Indices: SDAX, TecDax,
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2115452

 
End of News EQS News Service

2115452  10.04.2025 CET/CEST

Visual performance / price development - Eckert & Ziegler SE
Smart analysis and research tools can be found here.
MIC: XETR
Power-Shortcuts

Eckert & Ziegler AG

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2025
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.